BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20617378)

  • 1. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
    Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
    Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
    Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer.
    Magkou C; Mylona E; Theohari I; Giannopoulou I; Papanikolaou E; Markaki S; Nakopoulou L
    In Vivo; 2007; 21(6):967-72. PubMed ID: 18210742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer.
    Benesch C; Schneider C; Voelker HU; Kapp M; Caffier H; Krockenberger M; Dietl J; Kammerer U; Schmidt M
    Anticancer Res; 2010 May; 30(5):1689-94. PubMed ID: 20592362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.
    Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
    Eur J Cancer; 2005 May; 41(7):1017-25. PubMed ID: 15862750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer.
    Al-Bazz YO; Underwood JC; Brown BL; Dobson PR
    Eur J Cancer; 2009 Mar; 45(4):694-704. PubMed ID: 19138840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
    Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
    Watzka SB; Setinek U; Stubenberger EB; Tötsch M; Dekan G; Marcher M; Fleck T; Müller MR
    Eur J Cardiothorac Surg; 2011 Feb; 39(2):180-4. PubMed ID: 20580243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach.
    Lugli A; Zlobec I; Minoo P; Baker K; Tornillo L; Terracciano L; Jass JR
    Hum Pathol; 2006 Aug; 37(8):1022-31. PubMed ID: 16867865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
    Lim WT; Zhang WH; Miller CR; Watters JW; Gao F; Viswanathan A; Govindan R; McLeod HL
    Oncol Rep; 2007 Apr; 17(4):853-7. PubMed ID: 17342327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.
    Wang C; Tran-Thanh D; Moreno JC; Cawthorn TR; Jacks LM; Wang DY; McCready DR; Done SJ
    Breast Cancer Res Treat; 2011 Sep; 129(2):373-86. PubMed ID: 21046228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.